Current Report Filing (8-k)
December 08 2020 - 6:01AM
Edgar (US Regulatory)
0000725363
false
0000725363
2020-12-07
2020-12-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (date of earliest event reported): December 7,
2020
CEL SCI CORP
(Exact
name of Registrant as specified in its charter)
Colorado
|
001-11889
|
84-0916344
|
(State
or other jurisdiction of incorporation)
|
(Commission
File No.)
|
(IRS
Employer Identification No.)
|
8229
Boone Blvd., #802
Vienna, Virginia 22182
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (703) 506-9460
N/A
(Former
name or former address if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425
under the Securities Act (17CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-14c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common
Stock
|
CVM
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§203.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§204.12b-2 of this chapter.
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other
Events.
On
December 7, 2020, the Company issued a press release, filed as
Exhibit 99, concerning the final review stage of the Company's
phase 3 clinical trial involving Multikine.
Item 9.01 Financial Statements and Exhibits.
Exhibit
Number
|
|
Description
|
|
|
Press
Release re. Phase 3 Cancer Trials
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CEL-SCI CORPORATION
|
|
|
|
|
|
Date:
December 7, 2020
|
By:
|
/s/ Patricia
B. Prichep
|
|
|
|
Patricia
B. Prichep
|
|
|
|
Senior
Vice President of Operations
|
|
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024